> “…the focus of AI in drug discovery must shift from doing what can be done - such as modelling data that is readily available, but that is unlikely to move the needle - to doing what should be done, even if this requires, for example, substantial data generation…” It’s a worthy goal, but I think that many involved in this work might be thinking, even unconsciously, “You first”. This is the problem with AI for all o…
Here is an article by Pat Walters on the usefulness of ML in drug discovery. This article is a response to another one making the case that utility of ML models are very limited in drug discovery https://patwalters.github.io/Response-to-Peter-Kenny/ > (4a) revert to traditional methods but keep the veneer of using ML to save face I haven't worked in the industry side of things but in academia everyone kind of agrees…
AI in drug discovery – what it is, where we stand and the path forward
71–80 of 105 posts
Re: AI in drug discovery – what it is, where we stand and the path forward
#72> “…the focus of AI in drug discovery must shift from doing what can be done - such as modelling data that is readily available, but that is unlikely to move the needle - to doing what should be done, even if this requires, for example, substantial data generation…” It’s a worthy goal, but I think that many involved in this work might be thinking, even unconsciously, “You first”. This is the problem with AI for all o…
(3) seems like a problem in its own right? Basing science, traditional or newfangled ML, on such small amounts of data looks pretty weak.
You can do more tests on smaller things, like checking if some protein will kill some cells of a pest, but making sure a plant produces it enough that it actually does something significant to the real, live pests, that it's not toxic, and it doesn't harm the plant's yield massively (as it's now spending time producing your pesticide) is still going to take years. We might be able to fold proteins, but the kind of things we'd need to really simulate plant biology well enough to not need years of failures are still very far away.
And it's far worse in medicine, as with plants at least nobody has ethical concerns if they fail and die, and nobody needs to get consent from a corn seed. Getting to 50 actual data points from many medical studies is already a lot of effort. And imagine when it's a long term study, and you need to follow patients for 30 years, as theym move, or die, or decide to stop participating, or who knows what.
Re: AI in drug discovery – what it is, where we stand and the path forward
#73Re: AI in drug discovery – what it is, where we stand and the path forward
#74Earlier quoted context omitted.
I’m on 0.5 to 1mg oral minoxidil daily for a few years now and it’s working great. Blood pressure benefits too.
Any other side effects? I’ve never even heard of this.
Re: AI in drug discovery – what it is, where we stand and the path forward
#75[AI drug discovery] was never the hard part.
This made me laugh, more than expected, but I did visit LinkedIn just before so that could explain it. Thanks!
Re: AI in drug discovery – what it is, where we stand and the path forward
#76Earlier quoted context omitted.
There is one! Ketamin should have huge impacts on neuro/brain plasticity when used properly (i.e. in therapy)
Psychedelics are several orders of magnitude stronger on the plasticity front. In therapy as well.
Re: AI in drug discovery – what it is, where we stand and the path forward
#77> “…the focus of AI in drug discovery must shift from doing what can be done - such as modelling data that is readily available, but that is unlikely to move the needle - to doing what should be done, even if this requires, for example, substantial data generation…” It’s a worthy goal, but I think that many involved in this work might be thinking, even unconsciously, “You first”. This is the problem with AI for all o…
Re: AI in drug discovery – what it is, where we stand and the path forward
#78need one for brain plasicity. it would be nice to be able to easily learn a foreign language or musical instrument naturally.
Psilocybin has this effect. Source: I can't remember where I read it, so low confidence.
Same with ketamine. It's not like you can take it a couple of times and open some magic window where everything suddenly becomes easier to learn. From my personal experience and surface-level understanding of the current research, psychedelics(including ketamine) seem to temporarily relax hardened beliefs/priors and rigid neural pathways, which can help you see things from a fresh perspective. But learning something substantial like math or a new language after you've passed the most plastic stages of development is still going to take much longer than what these drugs can realistically help with.
They might make you see something differently or even get you extremely interested in it, but sustaining that interest and consolidating the knowledge or skill is still slow compared with childhood/adolescence. Of course, it depends a lot on what you're learning. For example, crystallized intelligence and sufficient motivation can make some things much easier to learn as an adult, but many useful things are also just boring to learn when you no longer have a childlike plastic brain or an environment built around constant learning.
Edit: Theoretically, you could accelerate learning by taking psychedelics/ketamine at a set frequency but it's a huge gamble because of their risk profile. eg. HPPD/trauma risk with classic psychedelics and bladder/neurotoxicity risk with ketamine if you get addicted or take it too frequently.
Re: AI in drug discovery – what it is, where we stand and the path forward
#79Earlier quoted context omitted.
(3) seems like a problem in its own right? Basing science, traditional or newfangled ML, on such small amounts of data looks pretty weak.
I worked on some of the very best funded plant research out there. When it comes down to it, there's enough variation caused by confounding factors, and it takes so long to capture more data, that almost everything anyone tries cannot be called a success or a failure for years, because the individual measurements for one small plot of land somewhere just don't mean anything. Once you do an entire experiment for a sea…
Re: AI in drug discovery – what it is, where we stand and the path forward
#80Earlier quoted context omitted.
Isn't the comment in fact praising Derek Lowe as a science communicator? In the second paragraph OP is just posing the questions that one might have when reading about a field not your own, that highlight the importance of reliable science communicators.
It's a very confusing comment since Derek Lowe is a chemist working in pharma but is being referred to only as a science communicator which I suspect most people would consider to be an implicit insult.